AU Patent

AU2017231824B2 — Acyclic antivirals

Assigned to Janssen Biopharma Inc · Expires 2021-07-01 · 5y expired

What this patent protects

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs

USPTO Abstract

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs

Drugs covered by this patent

Patent Metadata

Patent number
AU2017231824B2
Jurisdiction
AU
Classification
Expires
2021-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.